Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Hepatocellular 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 61Cisplatin 37Carboplatin 23Radiotherapy 21Cetuximab 19Magnetic Resonance Spectroscopy 18Paclitaxel 17Specimen Handling 13Docetaxel 12Fluorouracil 11Nivolumab 10tislelizumab 9Surgical Procedures, Operative 8Radiotherapy, Intensity-Modulated 7Radiation 7cemiplimab 6Standard of Care 6Platinum 6Chemoradiotherapy 6Biopsy 61,2-diaminocyclohexaneplatinum II citrate 6toripalimab 5Drug Therapy 5130-nm albumin-bound paclitaxel 5atezolizumab 4Taxes 4Ipilimumab 4Immunotherapy 4Fluorodeoxyglucose F18 4Cyclophosphamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Squamous Cell Carcinoma of Head and Neck × Rosiglitazone × Clear all
NCT04114136 2026-04-24

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

University of Pittsburgh

Phase 2 Recruiting
72 enrolled
DermatologicGastrointestinalHead & Neck

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hepatocellular, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡